

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 March 2006 (09.03.2006)

PCT


(10) International Publication Number
WO 2006/025623 A1

- (51) International Patent Classification⁷: **A61K 38/16**
- (21) International Application Number:
PCT/KR2004/002190
- (22) International Filing Date: 31 August 2004 (31.08.2004)
- (25) Filing Language: Korean
- (26) Publication Language: English
- (71) Applicant (for all designated States except US):
SUNGKYUNKWAN UNIVERSITY [KR/KR]; 53,
Myeongnyun-dong 3-ga, Jongno-gu, Seoul 110-745 (KR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SONG, Jae-hwan [KR/KR];** #B-802, Tripolis, Geumgok-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-943 (KR). **OH, Wonkyung [KR/KR];** #107-1007, Moa 2-cha Apt., Bongnim-dong, Nam-gu, Gwangju 503-752 (KR). **Pyo, Suhk Neung [KR/KR];** #1302-202, Mokdong Apt., 327, Sinjeong-dong, Yangcheon-gu, Seoul 158-070 (KR). **YANG, Joo-Sung [KR/KR];** #103-1503, Hyundai 1-cha Apt., Bangbae 4-dong, Seocho-gu, Seoul 137-937 (KR).

- LEE, Han-Woong [US/KR];** #318-2902 Sibeomdanji, SibeonHanyang Apt., Seohyeon-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-776 (KR). **LEE, Sung Ryul [KR/KR];** #603-1302, Shinhan Apt., Dahyun Maeul, 344 Gugal-ri, Giheung-eup, Yongin-si, Gyeonggi-do 449-903 (KR). **SUNG, Young Hoon [KR/KR];** #3-306, Chunrok Apt., 276-3 Yuljeon-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-230 (KR).
- (74) Agent: **SON, Min;** 19th Floor, City Air Tower, 159-9 Samsung-dong, Kangnam-gu, Seoul 135-973 (KR).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: COMPOSITION FOR TREATING VIRUS INFECTION DISEASE COMPRISING JAB1



(57) Abstract: Disclosed is a composition for treating or preventing a viral infection or associated disease comprising a Jab1 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a Jab1 protein.

WO 2006/025623 A1



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with a declaration as to non-prejudicial disclosures or exceptions to lack of novelty

Declaration under Rule 4.17:

- as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v)) for all designations

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMPOSITION FOR TREATING VIRUS INFECTION DISEASE COMPRISINGJAB1Technical Field

The present invention relates, in general, to a
5 composition for treating a viral infection comprising Jab1.
More particularly, the present invention relates to a
composition for treating or preventing a viral infection
comprising a Jab1 (Jun-activation binding protein 1)
protein, a nucleic acid having a nucleotide sequence coding
10 for a Jab1 protein or a recombinant virus expressing a Jab1
protein.

Background Art

Flavivirus and pestivirus belong to the *Flaviviridae*
family which possesses a single-stranded positive sense RNA
15 genome and causes various diseases in vertebrate hosts.
West Nile virus (WNV) (Burt et al., *Emerg Infect Dis.*,
8(8):820-826, 2002; Asnis et al., *Clin Infect Dis* 30(3): 413-
418, 2000) causes diseases including fever, rash, arthralgia
and myalgia when infecting susceptible hosts. Apoptosis in
20 wild-type WNV-infected brain cells is induced in a Bax-
dependent manner (Parquet et al., *FEBS Lett.*, 500(1-2):17-
24, 2001), and the apoptosis is induced by the capsid protein

of WNV through the mitochondrial/caspase-9 pathway (Yang et al., *Emerg Infect Dis.*, 8(12):1379-1384, 2002). However, the intracellular pathological mechanism of West Nile virus infection has not been completely understood.

5 Immunoglobulins and antiviral agents such as interferon alpha-2b and ribavirin were conventionally used for preventing and treating West Nile virus infection (Agrawal and Petersen., *J Infect Dis*, 188(1):1-4, 2003; Morrey et al., *Antiviral Res.*, 55(1):107-116, 2002 ; Anderson
10 et al., *Emerg Infect Dis.*, 8(1):107-108, 2002), but they have low therapeutic effects. At present, there is no effective drug for treating or preventing West Nile virus infection. Thus, there is a need for the development of such effective drugs.

15 On the other hand, Jab1 (Jun-activation binding protein 1) was initially known as a coactivator of AP-1 (Jun/Fos proto-oncogene) protein and has the following, various functions. Jab1 is a component (CSN5) of the COP9 signalosome (CSN) (Wei et al., *Annu Rev Cell Dev Biol.*,
20 19:261-286, 2003), and Jab1/CSN5 exists in a wide spectrum of organisms, ranging from yeasts to plants and animals. Overexpression of Jab1 causes the translocation of cyclin dependent kinase inhibitor p27/Kip1 from the nucleus to the cytoplasm, accelerates the Ub-26S proteasome-dependent
25 degradation, and participates in the G1-S transition of the cell cycle, mediated by p27/Kip1 (Tomoda et al., *Nature*,

398(6723):160-165, 1999). In addition, Jab1 involves the nuclear translocation of PGP9.5 that is overexpressed in primary lung cancer cells (Caballero et al., Oncogene, 21(19):3003-3010, 2002). Jab1 interacts with p53, Smad4 and
5 lutropin/choriogonadotropin receptor and stimulates degradation of these proteins (Bech-Otschir et al., EMBO J., 20(6):1630-1639, 2001; Li et al. J Biol Chem., 275(18):13386-13393, 2000; Wan et al., EMBO J., 3(2):171-176, 2002). Taken together, Jab1 translocates proteins from the nucleus to the
10 cytoplasm by interaction with intracellular proteins and thus stimulates protein degradation in a proteasome-dependent manner.

However, there is no report for interaction between Jab1 and viral proteins upon flavivirus infection.

15 Based on this background, the present inventors identified Jab1 as a protein interacting with the capsid protein of flavivirus, and found that Jab1 inhibits apoptosis by accelerating degradation of the capsid protein and that Jab1 is useful for treating or preventing a viral infection ,
20 thereby leading to the present invention.

Disclosure of the Invention

It is therefore an object of the present invention to provide a composition for treating or preventing a flavivirus or pestivirus infection, which comprises a Jab1

(Jun-activation binding protein 1) protein.

It is another object of the present invention to provide a composition for treating or preventing a flavivirus or pestivirus infection, which comprises a
5 nucleic acid having a nucleotide sequence coding for a Jab1 protein.

It is a further object of the present invention to provide a composition for treating or preventing a flavivirus or pestivirus infection, which comprises a
10 recombinant virus expressing a Jab1 protein.

It is yet another object of the present invention to provide a method of treating or preventing a flavivirus or pestivirus infection, which is based on administering a pharmaceutically effective amount of a Jab1 protein to a
15 subject requiring treatment or prevention of a viral infection.

It is still another object of the present invention to provide a method of treating or preventing a flavivirus or pestivirus infection, which is based on administering a
20 pharmaceutically effective amount of a nucleic acid having a nucleotide sequence coding for a Jab1 protein to a subject requiring treatment or prevention of a viral infection.

It is still another object of the present invention
25 to provide a method of treating or preventing a flavivirus or pestivirus infection, which is based on administering a

pharmaceutically effective amount of a recombinant virus expressing a Jab1 protein to a subject requiring treatment or prevention of a viral infection.

It is still another object of the present invention
5 to provide a method of assaying a substance stimulating expression of a Jab1 protein.

Brief Description of the Drawings

The above and other objects, features and other advantages of the present invention will be more clearly
10 understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

Fig. 1 shows the results of immunofluorescence analysis for expression patterns of the capsid (Cp) protein of West Nile virus (WNV) in three tumor cell lines;

15 Fig. 2 shows the results of immunofluorescence analysis for expression patterns of WNV-Cp in SK-N-SH cells;

Fig. 3 shows the results of an annexin assay, displaying apoptosis induction by WNV-Cp in two tumor cell
20 lines;

Fig. 4 shows the results of FACS analysis, displaying apoptosis induction by WNV-Cp in 293T cells;

Fig. 5 shows the procedure of a yeast two hybrid assay resulting in obtainment of clones expressing proteins

interacting with WNV-Cp;

Fig. 6 shows the results of immunofluorescence analysis, revealing that Jab1 translocates WNV-Cp from the nucleolus to the cytoplasm;

5 Fig. 7 shows the results of immunoprecipitation, revealing that Jab1 interacts with WNV-Cp;

Fig. 8 shows that co-expression of Jab1 and WNV-Cp leads to a decrease in caspase activity;

10 Fig. 9 shows the results of Western blotting, displaying that degradation of WNV-Cp by Jab1 is remarkably suppressed in the presence of a 26S proteasome inhibitor LLnL;

15 Fig. 10 shows the results of FACS analysis, displaying an apoptosis rate of normal cells not transfected with a C2-Cp gene;

Fig. 11 shows the results of FACS analysis, displaying an apoptosis rate of cells transfected with a pEGFP-C2-Cp plasmid;

20 Fig. 12 shows the results of FACS analysis, displaying an apoptosis rate of cells transfected with a pEGFP-N1 plasmid;

25 Fig. 13 shows the results of FACS analysis, displaying an apoptosis rate of cells transfected with a pEGFP-C2-Cp plasmid and treated with 200 nM of a PI3K inhibitor;

Fig. 14 shows the results of FACS analysis,

displaying an apoptosis rate of cells transfected with a pEGFP-C2-Cp plasmid and treated with 5 μ M of an Akt inhibitor;

Fig. 15 shows the results of FACS analysis, displaying an apoptosis rate of cells transfected with a pEGFP-C2-Cp plasmid and treated with 50 μ M of an Akt inhibitor;

Fig. 16 shows the results of Western blotting, displaying that p53 expression decreases with increasing concentrations of Jab1;

Fig. 17 shows a process of constructing a vector system for establishing a Jab1 adenovirus stable cell line; and

Fig. 18 shows the results of Western blotting, demonstrating that a NIH3T3 Jab1 retrovirus stable cell line is successfully established.

Best Mode for Carrying Out the Invention

In one aspect, the present invention provides a composition for treating or preventing a flavivirus or pestivirus infection comprising a Jab1 protein.

Viral infections and associated diseases intended to be treated or prevented according to the present invention are flavivirus and pestivirus infections. Flavivirus and pestivirus according to the classification of International

Committee on Taxonomy of viruses, belong to the *Flaviviridae* family, which possesses a positive-stranded single strand RNA genome and has a natural host range including vertebrates and arthropods. Flavivirus and pestivirus virions consist of an envelope and a nucleocapsid. Flavivirus virions are spherical and 40-50 nm in diameter, and pestivirus virions are spherical to pleomorphic and 40-60 nm in diameter. Flavivirus and pestivirus have a very similar structure and infection mechanism and induce apoptosis of infected cells.

Flavivirus includes the mammalian tick-borne virus group, seabird tick-borne virus group, Aroa virus group, Dengue virus group, Japanese encephalitis virus group, Ntaya virus group, Kokobera virus group, Spondweni virus group, Yellow fever virus group, Entebbe virus group, Modac virus group and Rio Bravo virus group. The present composition may be preferably applied to an infection with the Japanese encephalitis virus group. The Japanese encephalitis virus group includes Cacipacore virus, koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Usutu virus, West Nile virus, and Yaounde virus.

Pestivirus includes Border disease virus, bovine viral diarrhea virus 1, Bovine viral diarrhea virus 2, and Classical swine fever virus.

The present inventors, via a yeast two hybrid assay,

found that Jab1 is a protein directly interacting with the capsid (Cp) protein of West Nile virus, which induces apoptosis in WNV-infected cells, and investigated the effect of Jab1 on the capsid protein. As a result, Jab1 was
5 found to directly interact with the capsid protein, translocate the capsid protein from the nucleus to the cytoplasm and stimulate degradation of the capsid protein, thereby remarkably inhibiting apoptosis mediated by the viral capsid protein.

10 The Capsid denotes the protein shell that encloses the viral nucleic acid and is formed by multiple copies of a single major structural subunit protein. The structural subunit protein forming the capsid is called the capsid protein. With respect to the objects of the present
15 invention, the capsid protein is the flavivirus or pestivirus capsid protein to which the Jab1 protein binds. The complete genome sequence of West Nile virus including the nucleic acid sequence of the capsid protein of West Nile virus, a member of flavivirus, is available from
20 GenBank under accession numbers AF206518, AF196835, AF202541 and M12294. The nucleic acid sequences of capsid proteins of other members of flavivirus and pestivirus are also available from GenBank, for example, for JEV, under accession numbers M18370, D90194 and D90195; for SLEV,
25 under accession number M16614; for YFV, under accession numbers AF094612, U17067, U17066, U54798, U21055, U21056

and X03700; for DENV, accession numbers M23027, U88535, U88536 and U88537); and for BVDV, accession number M31182.

The homology of the capsid protein between flavivirus and pestivirus, which possess the capsid protein capable of binding the Jab1 protein, is about 90%.

The Jab1 protein used in the present composition includes all Jab1 proteins derived from yeasts, plants and animals, which include a wild-type Jab1 protein and, as long as the function of binding to the flavivirus or pestivirus capsid protein and stimulating degradation of the capsid protein is retained, variants of the Jab1 protein made by deletions, insertions, non-conservative or conservative substitutions, or combinations thereof. In one embodiment, the Jab1 protein may have an amino acid sequence designated as SEQ ID No. 2, and substitution, insertion and deletion variants of this amino acid sequence may be useful in the present composition.

The variant of Jab1 means the protein that has a sequence in which one or more amino acid residues differ from a wild-type amino acid sequence. An insertion is typically made by the addition of a consecutive amino acid sequence of about 1 to 20 amino acids, or may be made with a longer sequence. A deletion is typically in the range of about 1 to 30 amino acid residues, or may be in part made in a longer sequence such as the absence of one domain. Such variants may be prepared by a chemical peptide

synthesis method or a DNA sequence-based recombinant method, which are known in the art (Sambrook et al., Molecular Cloning, Cold Spring Harbour Laboratory Press, New York, USA, 2d Ed., 1989). Amino acid exchanges in
5 proteins and peptides which do not generally alter the activity of the protein or peptide are known in the art (H. Neurath, R. L. Hill, The Proteins, Academic Press, New York, 1979). The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr,
10 Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu and Asp/Gly, in both directions.

In addition, the Jab1 protein, if desired, may be modified by phosphorylation, sulfation, acrylation,
15 glycosylation, methylation, farnesylation, and the like.

The variant or modified product may have the biological activity functionally identical to its natural form, or, if desired, may be made by altering the property of the natural form. It is preferably a protein that is
20 improved in enhanced structural stability against heat, pH, etc., and protein activity by alteration and modification of its amino acid sequence.

The Jab1 protein may be obtained by extraction and purification from nature according to a method well known
25 in the art (Merrifield, J. Amer. chem. Soc. 85:2149-2156, 1963), or may be obtained using a genetic recombination

technique.

When the protein is prepared by chemical synthesis, a polypeptide synthesis method well known in the art may be used.

5 In the case of using the genetic recombination technique, the Jab1 protein may be obtained by a process including inserting a nucleic acid coding for Jab1 into a suitable expression vector, transforming a host cell with the vector, cultivating the host cell to allow Jab1 to
10 express and recovering expressed Jab1 from the cultured host cell.

 As the expression vector for expressing the Jab1 protein, all common expression vectors may be used. Since expression levels and modification of proteins differ
15 according to host cells, the most suitable host cell may be selected according to the intended use. Available host cells include, but are not limited to, prokaryotic cells such as *Escherichia coli*, *Bacillus subtilis*, *Streptomyces*, *Pseudomonas*, *Proteus mirabilis* or *Staphylococcus*. Among
20 them, *E. coli* is most commonly used. In addition, useful as host cells are lower eukaryotic cells, such as fungi (e.g., *Aspergillus*) and yeasts (e.g., *Pichia pastoris*, *Saccharomyces cerevisiae*, *Schizosaccharomyces*, *Neurospora crassa*), insect cells, plant cells, and cells derived from
25 higher eukaryotes including mammals.

 After a protein is expressed in a selected host cell,

it may be isolated and purified by a general biochemical isolation technique, for example, treatment with a protein precipitating agent (salting out), centrifugation, ultrasonic disruption, ultrafiltration, dialysis, and various chromatographies, such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography and affinity chromatography. Typically, these techniques are used in combinations of two or more to obtain highly pure isolation of a protein (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.(1982); Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press(1989); Deutscher, M., Guide to Protein Purification Methods Enzymology, vol. 182. Academic Press. Inc., San Diego, CA (1990)).

In another aspect, the present invention provides a composition for treating or preventing a flavivirus or pestivirus infection comprising a nucleic acid having a nucleotide sequence coding for a Jab1 protein.

The Jab1-encoding nucleotide sequence in the present composition, which encodes the Jab1 protein in the form of a wild type or a variant as described above, may be altered by substitutions, deletions, insertions or combinations thereof of one or more bases, and may be naturally occurring or chemically synthesized.

The chemical synthesis of the Jab1-encoding nucleotide sequence may be carried out by a synthesis method well known in the art, for example, as described in the literature: Engels and Uhlmann, Angew Chem IntEd Engl.,
5 37:73-127, 1988. Examples of the synthesis method include triester, phosphite, phosphoramidate and H-phosphate methods, PCR and other autoprimer methods, and oligonucleotide synthesis methods on solid phase supports.

In an embodiment, the Jab1-encoding nucleotide
10 sequence is exemplified as a nucleotide sequence encoding the amino acid sequence of SEQ ID No. 2, preferably a nucleotide sequence designated as SEQ ID No. 1.

A nucleic acid having the aforementioned nucleotide
15 sequence may be single-stranded or double-stranded, and may be DNA (genome, cDNA or synthetic) or RNA molecules.

In a preferred aspect, the Jab1-encoding nucleotide sequence is operably linked to a vector to provide a recombinant expression vector expressing the nucleotide sequence.

20 The term "vector", as used herein, means a vehicle for introducing a nucleic acid sequence (e.g., DNA, RNA, etc.) coding for a target gene into a host cell. Also, the term "expression vector", as used herein, which is a vector capable of expressing a target protein or target RNA in a
25 suitable host cell, refers to a genetic construct that comprises essential regulatory elements to which a gene

insert is operably linked thereto in such a manner as to be expressed in a host cell.

The term "operably linked", as used herein, refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter) and a second nucleic acid sequence coding for a target protein or RNA in a manner that allows general functions. For example, when a nucleic acid sequence coding for a protein or RNA is operably linked to a promoter, the promoter may affect the expression of a coding sequence. The operable linkage to a recombinant vector may be prepared using a genetic recombinant technique well known in the art, and site-specific DNA cleavage and ligation may be carried out using enzymes generally known in the art.

The vector useful in the present invention includes plasmid vectors, cosmid vectors and viral vectors. A suitable expression vector includes expression regulatory elements, such as a promoter, an operator, an initiation codon, a stop codon, a polyadenylation signal and an enhancer, and a signal sequence or leader sequence for membrane targeting or secretion, and may be prepared in various constructs according to the intended use. The initiation and stop codons are generally considered to be a portion of a nucleotide sequence encoding an immunogenic target protein. Also, the initiation and stop codons are necessary to be functional in an individual to whom a

genetic construct has been administered, and must be in frame with the coding sequence. The promoter of the vector may be constitutive or inducible. Also, the expression vector includes a selectable marker for selecting a host
5 cell containing a vector, and, in the case of being replicable, includes a replication origin. The vector may be self-replicated or integrated into host DNA.

In a more preferred aspect, the present invention provides a composition comprising a recombinant viral
10 vector carrying a nucleotide sequence coding for a Jab1 protein.

The term "recombinant viral vector", as used herein, typically denotes a viral vector that contains one or more exogenous genes, and, in the present invention, means a
15 viral vector carrying a Jab1 gene. The viral vector is preferably a replication-defective vector that lacks a replicon.

Non-limiting examples of the recombinant vector include recombinant viral vectors which are derived from
20 retrovirus, such as HIV (Human Immunodeficiency Virus), MLV (Murine Leukemia Virus), ASLV (Avian Sarcoma/Leukosis Virus), SNV (Spleen Necrosis Virus), RSV (Rous Sarcoma Virus) and MMTV (Mouse mammary tumor virus), adenovirus, adeno-associated virus, herpes simplex virus and etc.

25 The nucleic acid having a nucleotide sequence coding for a Jab1 protein may be delivered into target cells of a

patient for treating or preventing a viral infection by a method known in the art, for example, direct injection of a vector in naked DNA form (Wolff et al., Science, 247:1465-8, 1990; Wolff et al., J Cell Sci. 103:1249-59, 1992), or
5 using liposomes, cationic polymers, and the like. Liposomes are phospholipid membranes made by mixing cationic phospholipids such as DOTMA or DOTAP for gene delivery. When cationic liposomes are mixed with anionic nucleic acids in a predetermined ratio, nucleic acid-liposome
10 complexes are formed. These complexes are internalized into cells by endocytosis and stay in the endosome (Schaefer-Ridder M et al., Science. 215(4529):166-168, 1982; Hodgson et al., Nat Biotechnol., 14(3):339-342, 1996). Release of an internalized gene from the endosome into the cytoplasm
15 and transport of the endosomally released gene from the cytoplasm to the nucleus determine the efficiency for gene transfer and therapy. This gene transfer allows repeated administration and ensures high safety due to low immunogenicity, but has a disadvantage of providing low
20 efficiency in gene expression. Cationic polymers used in gene transport include poly-L-lysine, spermine, polyethylenimine (PEI) and chitosan (Hashida, Br J Cancer., 90(6):1252-1258, 2004; Wiseman, Gene Ther., 10(19):1654-1662, 2003; Koping-Hoggard, Gene Ther., 8(14):1108-1121,
25 2001). When a gene is administered into the body in a complex form with a cationic polymer, in vivo detention

time and expression duration of the gene remarkably increased in comparison with the case of being administered in naked DNA form.

In a further aspect, the present invention provides a composition for treating or preventing a flavivirus or pestivirus infection comprising a recombinant virus expressing a Jab1 protein.

Since the infection of cells of a patient with infective viral particles manipulated to express Jab1 in infected cells results in an increase in the expression efficiency of Jab1, this method provides a highly therapeutic effect.

Non-limiting examples of recombinant viruses useful in the present composition comprising a recombinant virus include retroviruses, adenoviruses, adeno-associated viruses and herpes simplex virus. Preferred are retroviruses and adenoviruses, and more preferred are adenoviruses.

Retroviruses have an advantage of providing long-lasting gene expression because they are irreversibly fused to the host chromosome. Adenoviruses, which are the most frequently used system in general gene therapy studies, are applicable to a wide spectrum of mammalian cells. Adeno-associated viruses have advantages of having a broad range of host cells where a therapeutic gene is delivered, fewer side effects on the immune system upon repeated

administration and a long duration of gene expression. Herpes simplex virus is a highly neurotropic virus, which infects neural cells where its genome remains as a stable episomal element within the nucleus of neural cells without
5 disturbing normal function of neural cells. When a replication-deficient herpes simplex virus was used for gene delivery, expression of a reporter gene in the nervous system was found to be sustained for a period of over one year.

10 In yet another aspect, the present invention provides a method of treating or preventing a flavivirus or pestivirus infection, which is based on administering, to a subject requiring treatment or prevention of a viral infection, a pharmaceutically effective amount of a Jab1
15 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a Jab1 protein.

The Jab1 protein, nucleic acid having a nucleotide sequence coding for a Jab1 protein or recombinant virus
20 expressing a Jab1 protein, used in the treatment method of the present invention, is the same as described above.

The treatment method of the present invention is provided for preventing or treating a viral infection in vertebrates, which includes mammals such as humans and
25 livestock.

The pharmaceutical composition of the present

invention, comprising the aforementioned Jab1 protein, nucleic acid having a nucleotide sequence coding for a Jab1 protein or recombinant virus expressing a Jab1 protein, is used for treating or preventing an infection of a virus
5 belonging to the *Flaviviridae* family, preferably flavivirus or pestivirus. In particular, the present composition may be preferably used for treating or preventing a flavivirus infection. The aforementioned viruses are known to cause fever, rash, bleeding, jaundice, arthralgia, myalgia,
10 encephalitis and meningitis (Watt et al., *Am J Trop Med Hyg.*, 68(6):704-706, 2003; Anninger et al., *Clin Infect Dis.*, 38(7):55-56, 2004). The pharmaceutical composition of the present invention may be used for suppressing or treating the incidence of the aforementioned diseases.

15 The present composition may include a pharmaceutically acceptable carrier. Examples of the pharmaceutically acceptable carrier may include, for oral administration, binders, lubricants, disintegrators, excipients, solubilizing agents, dispersing agents,
20 stabilizing agents, suspending agents, pigments and aromatics; for injectable preparations, buffering agents, preservatives, analgesics, solubilizing agents, tonic adjusting agents and stabilizing agents; and for topical administration, bases, excipients, lubricants and
25 preservatives. The pharmaceutical composition of the present invention may be formulated into a variety of

dosage forms in combination with the aforementioned pharmaceutically acceptable carrier. For example, for oral administration, the pharmaceutical composition may be formulated into tablets, troches, capsules, elixirs, suspensions, syrups or wafers. For injectable preparations, the pharmaceutical composition may be formulated into a unit dosage form, such as a multidose container or an ampoule as a single-dose dosage form.

The pharmaceutical composition of the present invention may be administered via any of the common routes, if it is able to reach a desired tissue. Therefore, the present composition may be administered topically, orally, parenterally, intranasally, intravenously, intramuscularly, subcutaneously, intraocularly and intradermally, and may be formulated into solutions, suspensions, tablets, pills, capsules and sustained release preparations. Injectable preparations are preferred. Injection may be carried out subcutaneously, intramuscularly and intravenously.

The present composition may be administered in a therapeutically or preventively effective amount. The dosage may vary according to the patient's age and sex, type and severity of the illness, administration routes, target cells and expression levels, and may be easily determined by an expert in the art.

In still another aspect, the present invention relates to a method of screening a compound stimulating expression of

a Jab1 protein, comprising: (a) culturing a cell expressing the Jab1 protein; (b) contacting the cell cultured at (a) with candidate compounds for stimulating expression of the Jab1 protein; (c) comparing an expression level of the Jab1 protein at (b) with that in a control not contacted with the candidate compounds; and (d) identifying a compound increasing expression levels of the Jab1 protein.

In still another aspect, the present invention relates to a method of screening a compound stimulating interaction between a Jab1 protein and a capsid (Cp) protein, comprising: (a) culturing a cell transformed with both a recombinant vector expressing the Jab1 protein and another recombinant vector expressing the Cp protein of flavivirus or pestivirus; (b) contacting the cell cultured at (a) with candidate compounds for stimulating interaction between the Jab1 protein and the Cp protein; (c) comparing an expression level of the Cp protein at (b) with that in a control not contacted with the candidate compounds; and (d) identifying a compound reducing expression levels of the Cp protein.

In the above screening method, the Cp protein of flavivirus or pestivirus, and preferably the Cp protein of West Nile virus, may be used.

Decreased or increased expression levels of the Jab1 and Cp proteins may be detected in protein or mRNA levels.

Protein expression levels may be detected by electrophoresis where each protein is loaded onto a gel, and

preferably by immunoassay where the amount of formed antigen-antibody complexes are assayed using an antibody to the Jab1 or Cp protein. Examples of these analysis methods include Western blotting, RIA and immunoprecipitation assay.

5 In the above detection method, the amount of antigen-antibody complexes formed may be quantitatively analyzed based on the size of signals of a detection label. The detection label may be selected from the group consisting of enzymes, fluorescent materials, ligands, luminescent
10 materials, microparticles, redox molecules and radioisotopes, but the present invention is not limited to these examples.

 The antigen-antibody complex formation may be detected using one selected from the group consisting of a colorimetric method, an electrochemical method, a
15 fluorimetric method, luminometry, a particle counting method, visual assessment and a scintillation counting method, but the present invention is not limited to the examples.

 mRNA expression levels may be detected by a method using primers specific for the Jab1 or Cp protein. Examples
20 of the method include RT-PCR and Northern blotting. Preferred is RT-PCR, a simple analysis method that allows quantitative analysis of transcription of Jab1 or Cp to mRNA by analysis of band patterns and intensity.

 The present invention will be explained in more detail
25 with reference to the following examples in conjunction with the accompanying drawings. However, the following examples

are provided only to illustrate the present invention, and the present invention is not limited to the examples.

EXAMPLE 1: Expression of the WNV-Cp protein in human cells

To investigate the expression patterns of the WNV capsid (WNV-Cp) protein in various human cell lines, human
5 kidney 293T cells (ATCC), osteosarcoma U2OS cells (ATCC), HeLa cells (ATCC) and human neuroblastoma SK-N-SH cells (ATCC) were transfected with a vector carrying a WNV-Cp gene using a Lipofectamine reagent, and were subjected to
10 immunofluorescent staining.

Primarily, a WNV-Cp gene was amplified by PCR using pcDNA3.1WNV-Cp as a template and primers designated as SEQ ID Nos. 3 and 4, and the WNV-Cp DNA was digested with EcoRI and XhoI and inserted into a pcDNA3HA plasmid, thus
15 generating pcDNA3-HA/WNV-Cp. 293T, U2OS, HeLa and SK-N-SH cells were transfected with the pcDNA3-HA/WNV-Cp. After 24 hrs, the transfected cells were fixed and subjected to immunofluorescent staining using a primary HA-mouse monoclonal antibody (1:100 diluted; Santa Cruz) and a
20 secondary fluorescein isothiocyanate (FITC)-conjugated antibody (1:100 diluted; Sigma). Then, the expression of WNV-Cp (green) was observed using a UV confocal microscope. Nucleus was stained with DAPI(blue). The WNV-Cp protein was found to exist in the nucleolus in 293T, U2OS and HeLa

cells (Fig. 1) and in the cytoplasm in SK-N-SH cells (Fig. 2).

The existence in the cytoplasm of WNV-Cp present mainly in the nucleolus indicates that WNV-Cp interacts
5 with some intracellular proteins.

EXAMPLE 2: Apoptosis induction by WNV-Cp in human cells

The WNV-Cp protein is known to induce apoptosis by previous studies revealing that the WNV-Cp protein, in HeLa cells, induces nuclear condensation that is a typical
10 feature of cells undergoing apoptosis, and such apoptosis occurs via the capase-9 pathway. In this test, these facts were confirmed by annexin-V staining and PI staining.

Primarily, a WNV-Cp gene was amplified by PCR using pcDNA3.1WNV-Cp as a template and primers designated as SEQ
15 ID Nos. 3 and 7. The amplified WNV-Cp DNA was digested with EcoRI and BamHI and inserted into a pEGFP-C2 plasmid, thus generating pEGFP-WNV-Cp. Then, 293T and U2OS cells were individually transfected with a GFP expression vector, pEGFP-C2 (control vector; CLONTECH) and the pEGFP-WNV-Cp.
20 After 24 hrs, the cells were stained with annexin-V (red) to bind annexin-V to an apoptosis indicator, phosphatidyl serine that is externalized upon apoptosis, and were observed under a Carl Zeiss vision microscope. As a result, apoptosis occurred in the cells with transfected the pEGFP-

WNV-Cp (Fig. 3).

Separately, 293T cells were transfected with pEGFP-C2 (control vector) and pEGFP-WNV-Cp. After 48 hrs, cell lysates were collected, stained with PI (propidium iodide) to measure apoptosis, and subjected to FACS analysis. The transfection with the control vector pEGFP resulted in an apoptosis rate of 15.97%, and the transfection with the pEGFP-WNV-Cp resulted in an apoptosis rate of 27.03% (Fig. 4).

10 EXAMPLE 3: Screening for proteins interacting with WNV-Cp

A possible mechanism of the apoptosis induction by WNV-Cp involves direct or indirect interaction of the capsid protein with regulators capable of causing apoptosis. In this regard, to better understand the apoptosis induction by the capsid protein, the regulators interacting with WNV-Cp need to be screened. For screening the regulators, a yeast two hybrid assay was performed using a cDNA library from human brain tissue that is a major infection site of West Nile virus.

20 Primarily, a WNV-Cp gene (450bp) was amplified by PCR using pcDNA3.1 WNV-Cp as a template and primers designated as SEQ ID Nos. 3 and 4, below. The amplified WNV-Cp gene was cloned into EcoRI/SalI sites of a pGBK-T7 vector containing a TRP1 marker and a Gal4-DNA binding domain,

thus generating a pGBK-T7 WNV-Cp construct.

Forward primer (SEQ ID No. 3):

5'-CCG GAA TTC TCT AAA AAA CCA GGT GGC CCC GG-3'

Reverse primer (SEQ ID No. 4):

5 3'-CCG CTC GAG CTA CGC GCC CAC GCT GGC GAT CAG-5'

The yeast two hybrid assay was carried out using the pGBK-T7 WNV-Cp plasmid as a bait and, as a prey, a human brain cDNA library (Clontech) carrying the LEU2 marker and fused to the downstream of the Gal4 activation domain. A yeast strain AH109 was transfected with the bait plasmid pGBK-T7 WNV-Cp by a lithium acetate method (Gietz et al. 1995), mixed for mating with another yeast strain Y187 transfected with 1 ml of the human brain cDNA library, and smeared onto fifty 150-mm SD plates lacking adenine, leucine, histidine and tryptophan. 945 colonies were obtained (the a of Fig. 5), and candidates to have the potential to interact with the capsid protein were selected on the same plate (the b of Fig. 5). For second screening, replica plating was carried out on the selection medium, SD/-Ade-Leu-His-Trp, and blue colonies were obtained (the c of Fig. 5). The blue colonies were tested again, and eventually, eighty clones were obtained (the d of Fig. 5). Yeast plasmid was isolated from the clones by lyticase-based cell disruption and subjected to DNA sequencing using primers designated as SEQ ID Nos. 5 and 6, below, followed

by blast searching for identifying corresponding proteins.

Forward primer (SEQ ID No. 5)

5'-CTA TTC GAT GAT GAA GAT ACC CCA CCA AAC CC-3'

Reverse primer (SEQ ID No. 6)

5 3'-AGT GAA CTT GCG GGG TTT TTC AGT ATC TAC GAT-5'

Eight proteins were identified, which were Jab1, TPRL1, RanBPM (RanBP9), PAP-1BP, Snapin (Synaptosomal-associated protein), Bassoon protein, a likely ortholog of mouse rabphilin3A and CG13214-PA.

10 EXAMPLE 4: Translocation of WNV-Cp by Jab1

To evaluate the effect of Jab1, identified to interact with WNV-Cp, on the intracellular location of WNV-cp, 293T, U2OS and HeLa cells were cotransfected with the WNV-Cp protein and Jab1. 293T, U2OS and HeLa cells were
15 cotransfected with HA-tagged pcDNA-HA/WNV-Cp and Flag-tagged pCMV Tag2B-Jab1. After 24 hrs, the cells were stained using an anti-HA antibody (green) and an anti-Flag antibody (red) and observed under a confocal microscope. As shown in Fig. 6, like Jab1, the immunofluorescence signal
20 for WNV-Cp appeared in the cytoplasm. A merge of two confocal images shows that WNV-Cp and Jab1 are expressed in the same site, cytoplasm, and PC (phase contrast) displays the whole cell morphology.

Separately, immunoprecipitation (IP) was performed to confirm the interaction between WNV-Cp and Jab1. 293T cells were cotransfected with Flag-Jab1 and HA-WNV-Cp plasmids, and the whole cell lysates were immunoprecipitated with an anti-HA mouse antibody. As a control, IP was carried out with an anti-Myc antibody. Immunoprecipitated proteins were run on a 12% SDS-PAGE gel, transferred to a nitrocellulose membrane, and detected with an anti-Flag mouse antibody to visualize immunoprecipitated Jab1 along with WNV-Cp (Fig. 7).

Jab1 was found to be co-immunoprecipitated with WNV-Cp. This result indicates that Jab1 interacts with WNV-Cp in 293T cells and translocates WNV-Cp from the nucleolus to the cytoplasm.

EXAMPLE 5: Inhibition of WNV-induced apoptosis by Jab1

WNV-Cp, which is a pathogenic protein, is known to induce apoptosis via the mitochondrial/caspase-9 pathway. In this regard, a caspase activity assay was performed to evaluate the effect of Jab1 on WNV-Cp-induced apoptosis.

293T cells were plated onto 60-mm plates at a density of 3×10^5 cells, cultured, and transfected with pcDNA3-HA, pcDNA3-HA/Cp, pCMV-tag2B-Jab1, both pcDNA3-HA/Cp and pCMV-tag2B-Jab1, and pcDNA3-Bax, respectively. After 24 hrs, the cells were washed with 1xPBS twice, transferred to 1.5-ml

tubes, and lysed with 20 μ l of buffer C (25% glycerol, 0.42 M NaCl, 1.5 M MgCl₂, 0.2 mM EDTA, 20 mM HEPES, 1 mM DTT, 0.5 mM PMSF, pH7.9). After being incubated for 10 min on ice, the lysed cells were centrifuged. The total protein concentration in each supernatant was measured, and samples of zero to 300 μ g of proteins were placed into a 96-well plate. To the 96-well plate, 50 μ l of 2 \times reaction buffer and 5 μ l of 4 mM DNA-conjugated substrate, provided in a caspase colorimetric substrate set II plus kit (Biovision), were added. After a 1-hr incubation at 37°C, the activity of caspase-3 and caspase-9 was measured at 410 nm using a microtiter plate reader. The results are given in the A panel of Fig. 8. In cells expressing WNV-Cp, the activity of caspase-3 and caspase-9 was similar to that in cells expressing Bax, a member of the pro-apoptotic Bcl-2 family. When cells co-expressed WNV-Cp and Jab1, the caspase activity was remarkably reduced. These results indicate that Jab1 suppresses the activation of caspase-3 and caspase-9 by WNV-Cp. The expression of the proteins used in this caspase activity assay was detected by Western blotting, and the results are given in the B panel of Fig. 8.

Taken together, these results indicate that Jab1 expressed in the cell suppresses WNV-Cp-induced apoptosis through the mitochondrial/caspase-9 pathway by translocating WNV-Cp from the nucleolus to the cytoplasm.

EXAMPLE 6: Degradation of WNV-Cp by Jab1

To determine whether Jab1 stimulates degradation of WNV-Cp, protein levels of WNV-Cp were assessed in cells treated with a 26S proteasome inhibitor, LLnL (Sigma).

5 293T cells were plated onto 60-mm plates at a density of 3×10^5 cells, cultured, and transfected with pcDNA3-HA/WNV-Cp alone, and pcDNA3-HA/WNV-Cp and pCMV-tag2B-Jab1 together using an Effectene transfection reagent (Qiagen). In the case of the co-transfection, to equalize the levels
10 of expressed DNA, 12 hrs after transfection, cells were divided into two plates by pipetting. 20 hrs after transfection, the cells were treated for 4 hrs with 20 $\mu\text{M}/\text{ml}$ of the proteasome inhibitor LLnL (N-acetyl-L-leucinylnorleucinal, Sigma). Then, the cells were washed
15 with 1x PBS and collected. Samples of 50 μg protein were loaded onto a SDS-PAGE gel and analyzed by Western blotting using an anti-HA antibody (Santa Cruz) for the detection of WNV-Cp expression and an anti-Flag M2 antibody (Sigma) for the detection of Jab1 expression. Actin was used as a
20 loading control.

Compared to the single expression of WNV-Cp, the co-expression with Jab1 resulted in a large decrease in protein levels of WNV-Cp (lanes 1 and 2 of Fig. 9). In contrast, upon the treatment with LLnL, the cotransfected

cells exhibited increased protein levels of WNV-Cp (lane 3 of Fig. 9). These results indicate that Jab1 accelerates the degradation of WNV-Cp.

5 Taken together, these results indicate that Jab1 suppresses the function of WNV-Cp by inducing the degradation of WNV-Cp through the ubiquitin proteasome pathway.

EXAMPLE 7: Inhibition of apoptosis using signal transduction pathway regulators

10 Human neuroblastoma SH-SY5Y cells were transfected with a WNV-Cp gene. To determine an apoptosis rate in cells expressing the capsid protein of WNV, the cells were stained with annexin V-PE and subjected to FACS analysis (BioRAD, Win BRYTE). As a result, the cells were
15 fractionated into four fractions: A, B, C and D. The A fraction indicates a cell population that was not injected with the WNV-Cp gene and stained with annexin V-PE. The B fraction displays a cell population that was injected with the WNV-Cp gene and stained with annexin V-PE. The C
20 fraction displays a cell population that was not injected with the WNV-Cp gene and not stained with annexin V-PE. The D fraction displays a cell population that was injected with the WNV-Cp gene and not stained with annexin V-PE.

Normal cells not injected with a C2-Cp gene displayed

an apoptosis rate of 14.0% (Fig. 10), and cells expressing WNV-Cp exhibited an apoptosis rate of 69.6% (Fig. 11). These results confirmed that WNV-Cp greatly increases apoptosis of cells. As a negative control, pEGFP-N1-
5 injected cells showed an apoptosis rate of 23.8% (Fig. 12), which was higher than as expected. This high apoptosis rate in the negative control is believed to be due to an EGFP signal being very strong and thus cross-linked with a FL2 signal, and may therefore be substantially lower.

10 Separately, SH-SY5Y cells were transfected with a WNV-Cp gene. After 6 hrs, the cells were treated with 200 nM of a PI3K inhibitor, wortmanin (Sigma), and 5 μ M and 50 μ M of an Akt inhibitor, calbiochem (CN Biosciences). After 24 hrs, the cells were stained with annexin V-PE that is
15 capable of detecting a step of apoptosis and subjected to FACS analysis (BioRAD, WinBryte) for measuring an apoptosis rate. About 10-30% of the cells were found to be successfully transfected with the WNV-Cp gene. The transfected cells were analyzed on a FL3 channel (green
20 fluorescence) and annexin V-PE binding was analyzed on a FL2 channel. An apoptosis rate in capsid-expressing cells was calculated according to Reaction 1, below. Cells transfected with a pEGFP-N1 plasmid were used as a negative control, and cells transfected with a C2-Cp plasmid and not
25 treated with the inhibitor were used as a positive control.

[Reaction 1]

[Annexin V-PE-positive cells/(all cells expressing
C2-Cp)] × 100

Cells expressing WNV-Cp displayed an apoptosis rate
5 of 69.6%. In contrast, when treated with 50 μ M of the Akt
inhibitor calbiochem and 200 nM of the PI3K inhibitor
wortmanin, these cells exhibited apoptosis rates of 15.9%
and 22.8%, respectively. That is, the treatment of the
inhibitors resulted in suppression of apoptosis induced by
10 WNV-Cp (Figs. 13,14 and 15). These results indicate that
the PI3K inhibitor and Akt inhibitor suppress the apoptosis
induced by the expression of WNV-Cp.

EXAMPLE 8: Decreased expression of endogenous p53 by Jab1

The COP9 signalosome-specific phosphorylation targets
15 the tumor suppressor gene p53 to degradation by the
ubiquitin-26S proteasome-dependent pathway (Bech-Otschir et
al., EMBO J., 20(7):1630-1639, 2001). On the assumption
that Jab1 interacts with p53 because it is a member of the
COP9 signalosome, Jab1 was evaluated for its effect on p53
20 expression.

U2OS cells were transfected with Flag/mdm2 (control)
and Flag/Jab1 with various concentrations of 1, 3 and 5 μ g
using a Lipofectamin/plus reagent (Invitrogen). After 48

hrs, cell lysates were collected, and total protein concentrations were measured by a BSA (PIERCE) method. Samples of 100 µg/ml protein were separated on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The blot was blocked with 5% skim milk for 30 min, and treated with a rabbit anti-HA antibody (Santa Cruz) and a mouse anti-Flag antibody (Sigma) to examine expression levels of p53 according to increased expression of mdm2 and Jab1. Expression of p53 was rarely affected by the control mdm2, but remarkably decreased with increasing concentrations of Jab1 (Fig. 16).

EXAMPLE 9: Establishment of Jab1 adenovirus stable cell line

A stable cell line producing an adenovirus inducing overexpression of Jab1 was established using an AdEasy XL adenoviral vector system (Stratagene). Jab1 was cloned into BglIII/PvuI sites of a pShuttle-IRES-hrGFP vector (the A and B of Fig. 17). The resulting pShuttle-IRES-hrGFP/Jab1 vector was purified by maxi preparation (maxi-prep), digested with PmeI, and transformed into an *E. coli* strain BJ5183 which contains AD1 (Stratagene) to produce homologous recombinant adenovirus plasmid. Emerged colonies were picked and grown in a culture broth, and plasmid DNA was isolated from the culture. Cloning was found to be

successful by restriction mapping with PacI (the C of Fig. 17). The plasmid was then amplified by being transfected into mammalian AD293 cells (Stratagene) using a Lipofectamin/plus reagent (Invitrogen). Produced adenovirus
5 was transfected again into AD293 cells, thus generating a stable cell line producing a recombinant adenovirus carrying a Jab1 gene, that is, a Jab1 adenovirus stable cell line.

The Ad1-Jab1 plasmid used in the production of the
10 adenovirus stable cell line was deposited at an international depository authority, KCCM (Korean Culture Center of Microorganisms; 2nd Floor, Yourim Building, 361-221, Hongje 1-dong Seodaemun-gu, Seoul, Korea) on August 31, 2004, and assigned accession number KCCM 10593.

15 EXAMPLE 10: Establishment of NIH3T3 Jab1 stable retrovirus cell line

A HA/Jab1 fragment excised from the pcDNA3-HA/Jab1 plasmid was subcloned into an EcoRI site of the pLPCX retroviral vector (BD Bioscience) capable of producing
20 retrovirus, thus generating pLPC/HA-Jab1. The pLPC/HA-Jab1 construct carrying a puromycin resistant gene was cotransfected with the pCL packaging plasmid (BD Bioscience) into 293T cells using a Lipofectamine reagent (Invitrogen). After two days, viral particles were purified

with a 0.45- μ m filter. 1 ml of the viral particles was diluted in 2 ml of medium and supplemented with 4 μ g/ml polybren (Sigma) helping viral infection, and infected NIH3T3 cells. After 24 hrs, the cells were selected in a medium containing 2 μ g/ml puromycin (Sigma), thereby generating a stable cell line producing a recombinant retrovirus carrying a Jab1 gene, that is, a Jab1 retrovirus stable cell line. A recombinant retrovirus produced by the stable cell line, Retro-Jab1, was deposited at an international depositary authority, KCCM (Korean Culture Center of Microorganisms; 2nd Floor, Yourim Building, 361-221, Hongje 1-dong Seodaemun-gu, Seoul, Korea) on August 31, 2004, and assigned access number KCCM 10592. In a control cell line not carrying an exogenous Jab1 gene and the retrovirus stable cell line highly expressing Jab1, expression levels of Jab1 and p53 were examined. The retrovirus stable cell line displayed high expression of Jab1 and decreased expression of p53 (Fig. 18).

The decreased expression of p53, shown in Fig. 18, correlated with the results of Example 8. These results indicate that stable gene transfer using a recombinant retrovirus overexpressing Jab1 leads to degradation of a viral capsid protein.

Industrial Applicability

As described hereinbefore, the present composition for treating a viral infection comprising Jabl is capable of effectively treating diseases caused by flavivirus or pestivirus infections, including fever, rash, bleeding, jaundice, arthralgia, myalgia, encephalitis and meningitis.

Applicant's or agent's File reference PCTA9408-8	International application No. PCT/KR2004/002190
-----------------------------------------------------	----------------------------------------------------

INDICATIONS RELATING TO DEPOSITED MICROORGANISM

OR OTHER BIOLOGICAL MATERIAL

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>37</u> , line <u>9-14</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are on an additional sheet <input type="checkbox"/>	
Name of depositary institution Korean Culture Center of Microorganisms (KCCM)	
Address of depositary institution (including postal code and country) 2nd Floor, Yulim Bldg, 361-221, Hongje 1-dong, Seodaemun-gu, Seoul, 120-091, Korea	
Date of deposit 31/08/2004	Accession Number KCCM 10592
C. ADDITIONAL INDICATIONS (leave it blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For international Bureau use only
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Applicant's or agent's File reference PCTA9408-8	International application No. PCT/KR2004/002190
-----------------------------------------------------	----------------------------------------------------

INDICATIONS RELATING TO DEPOSITED MICROORGANISM

OR OTHER BIOLOGICAL MATERIAL

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>36</u> , line <u>10-15</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are on an additional sheet <input type="checkbox"/>	
Name of depositary institution Korean Culture Center of Microorganisms (KCCM)	
Address of depositary institution (including postal code and country) 2nd Floor, Yulim Bld., 361-221, Hongje 1-dong, Seodaemun-gu, Seoul, 120-091, Korea	
Date of deposit 31/08/2004	Accession Number KCCM 10593
C. ADDITIONAL INDICATIONS (leave it blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau Inter (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For international Bureau use only
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Claims

1. A composition for treating or preventing a flavivirus or pestivirus infection, comprising a Jab1 (Jun-activation binding protein 1) protein.

5 2. The composition as set forth in claim 1, wherein the Jab1 protein has an amino acid sequence designated as SEQ ID No. 2.

 3. The composition as set forth in claim 1, wherein the Jab1 protein is encoded by a nucleotide sequence
10 designated as SEQ ID No. 1.

 4. A composition for treating or preventing a flavivirus or pestivirus infection, comprising a nucleic acid having a nucleotide sequence coding for a Jab1 protein.

15 5. The composition as set forth in claim 4, wherein the nucleic acid having the nucleotide sequence coding for the Jab1 protein is a recombinant vector having a nucleotide sequence coding for an amino acid sequence designated as SEQ ID No. 2.

20 6. The composition as set forth in claim 4, wherein

the nucleic acid having the nucleotide sequence coding for the Jab1 protein is a recombinant vector having a nucleotide sequence designated as SEQ ID No. 1.

7. The composition as set forth in claim 5 or 6,
5 wherein the recombinant vector is a recombinant viral vector.

8. The composition as set forth in claim 7, wherein the recombinant viral vector is selected from among recombinant retrovirus, adenovirus, adeno-associated virus
10 and herpes simplex virus.

9. A composition for treating or preventing a flavivirus or pestivirus infection, comprising a recombinant virus expressing a Jab1 protein.

10. The composition as set forth in claim 9, wherein
15 the recombinant virus expressing the Jab1 protein is a recombinant virus expressing a Jab1 protein having an amino acid sequence designated as SEQ ID No. 2.

11. The composition as set forth in claim 9, wherein the recombinant virus expressing the Jab1 protein is a
20 recombinant virus expressing a Jab1 protein encoded by a nucleotide sequence designated as SEQ ID No. 1.

12. The composition as set forth in claim 9, wherein the recombinant virus is selected from among adenovirus, adeno-associated virus and herpes simplex virus.

13. The composition as set forth in claim 12, wherein
5 the recombinant virus is selected from among retrovirus and adenovirus.

14. The composition as set forth in any one of claims 1, 4 and 9, wherein the infection is a flavivirus infection.

10 15. The composition as set forth in claim 14, wherein the flavivirus is West Nile virus.

16. The composition as set forth in any one of claims 1, 4 and 9, wherein the infection is associated with fever, rash, bleeding, jaundice, arthralgia, myalgia, encephalitis
15 or meningitis.

17. A method of screening a compound stimulating expression of a Jab1 protein, comprising:

- (a) culturing a cell expressing the Jab1 protein;
- (b) contacting the cell cultured at (a) with
20 candidate compounds for stimulating expression of

the Jab1 protein;

(c) comparing an expression level of the Jab1 protein at (b) with that in a control not contacted with the candidate compounds; and

5 (d) identifying a compound increasing expression levels of the Jab1 protein.

18. A method of screening a compound stimulating interaction between a Jab1 protein and a capsid (Cp) protein, comprising:

10 (a) culturing a cell transformed with both a recombinant vector expressing the Jab1 protein and another recombinant vector expressing the Cp protein of flavivirus or pestivirus;

(b) contacting the cell cultured at (a) with candidate
15 compounds for stimulating interaction between the Jab1 protein and the Cp protein;

(c) comparing an expression level of the Cp protein at (b) with that in a control not contacted with the candidate compounds; and


20 (d) identifying a compound reducing expression levels of the Cp protein.

19. The method as set forth in claim 17 or 18, wherein the comparison of expression levels at (c) is carried out in protein or mRNA levels.

20. The method as set forth in claim 19, wherein the comparison of expression levels is carried out by an immunoassay method.




21. The method as set forth in claim 19, wherein the
5 comparison of expression levels is carried out in mRNA levels by RT-PCT (Reverse Transcription-Polymerization Chain Reaction).

1/18
Fig. 1




2/18
Fig. 2

SK-N-SH





3/18

Fig. 3


Annexin assay

4/18


Fig. 4

FACS Analysis**pEGFP-C2****15.97%****pEGFP-Cp****27.03%****48h**

5/18
Fig. 5




6/18
Fig. 6



24h after transfection



7/18


Fig. 7




8/18

Fig. 8




9/18
Fig. 9

10/18
Fig. 10




11/18

Fig. 11




12/18
Fig. 12




13/18

Fig. 13




14/18


Fig. 14




15/18

Fig. 15




16/18
Fig. 16

17/18
Fig. 17



18/18
Fig. 18



sequence list.txt

<110> SUNGKYUNKWAN UNIVERSITY
 <120> Composition for treating virus infection disease comprising Jab1
 <160> 7
 <170> KopatentIn 1.71
 <210> 1
 <211> 1262
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> gene
 <222> (1)..(1262)
 <223> Jab1
 <220>
 <221> CDS
 <222> (94)..(1095)
 <400> 1
 ctggtgggga aggtccaaag ccgcacgct gaggccagc agaagaaagt tgcatttga 60
 ttgtggagcg acagcttctc cggtgcctcg gcc atg gca gct tcc ggg 108
 Met Ala Ala Ser Gly
 1 5
 agt ggt atg gcc cag aaa acc tgg gaa ttg gcc aac aac atg cag gaa 156
 Ser Gly Met Ala Gln Lys Thr Trp Glu Leu Ala Asn Asn Met Gln Glu
 10 15 20
 gcg cag agt atc gat gaa atc tac aaa tat gac aaa aaa caa caa caa 204
 Ala Gln Ser Ile Asp Glu Ile Tyr Lys Tyr Asp Lys Lys Gln Gln Gln
 25 30 35
 gaa atc ctg gcg gcg aaa ccc tgg act aag gat cac cac tac ttt aaa 252
 Glu Ile Leu Ala Ala Lys Pro Trp Thr Lys Asp His His Tyr Phe Lys
 40 45 50
 tac tgc aaa atc tca gca ttg gct cta ctg aaa atg gtg atg cat gcc 300
 Tyr Cys Lys Ile Ser Ala Leu Ala Leu Leu Lys Met Val Met His Ala
 55 60 65
 agg tca gga ggc aac ttg gaa gtg atg ggt ttg atg ctc ggg aaa gtc 348
 Arg Ser Gly Gly Asn Leu Glu Val Met Gly Leu Met Leu Gly Lys Val
 70 75 80 85
 gac ggc gag acc atg atc atc atg gac agt ttc gct ttg cct gta gag 396
 Asp Gly Glu Thr Met Ile Ile Met Asp Ser Phe Ala Leu Pro Val Glu
 90 95 100
 ggc aca gaa act cga gta aat gct caa gct gct gcg tat gag tat atg 444
 Gly Thr Glu Thr Arg Val Asn Ala Gln Ala Ala Ala Tyr Glu Tyr Met
 105 110 115
 gct gca tac ata gaa aat gcc aaa cag gtt ggc cgc ctt gag aat gca 492
 Ala Ala Tyr Ile Glu Asn Ala Lys Gln Val Gly Arg Leu Glu Asn Ala
 120 125 130
 atc ggt tgg tat cat agc cac cct ggt tat ggc tgc tgg ctc tcc ggg 540
 Ile Gly Trp Tyr His Ser His Pro Gly Tyr Gly Cys Trp Leu Ser Gly
 135 140 145
 att gat gtt agt aca cag atg ctg aac cag cag ttt caa gaa cca ttt 588
 Ile Asp Val Ser Thr Gln Met Leu Asn Gln Gln Phe Gln Glu Pro Phe
 150 155 160 165
 gta gca gtg gtg att gat cca acc aga aca atc tct gca gga aaa gtg 636
 Val Ala Val Val Ile Asp Pro Thr Arg Thr Ile Ser Ala Gly Lys Val
 170 175 180
 aat ctt ggc gcc ttt agg aca tat cca aag ggc tac aaa cct cct gat 684
 1 페이지

sequence list.txt

```

Asn Leu Gly Ala Phe Arg Thr Tyr Pro Lys Gly Tyr Lys Pro Pro Asp
185                               190                               195

gaa gga cct tct gag tac cag act atc cca ctt aat aaa ata gaa gat      732
Glu Gly Pro Ser Glu Tyr Gln Thr Ile Pro Leu Asn Lys Ile Glu Asp
200                               205                               210

ttt ggc gtg cac tgc aaa caa tat tat gcc tta gaa gtc tca tat ttc      780
Phe Gly Val His Cys Lys Gln Tyr Tyr Ala Leu Glu Val Ser Tyr Phe
215                               220                               225

aaa tca tct ttg gat cgt aaa cta ctt gag ctt ttg tgg aat aaa tac      828
Lys Ser Ser Leu Asp Arg Lys Leu Leu Glu Leu Leu Trp Asn Lys Tyr
230                               235                               240                               245

tgg gtg aat acc ctg agt tcc tct agc ttg ctt act aat gca gac tac      876
Trp Val Asn Thr Leu Ser Ser Ser Leu Leu Thr Asn Ala Asp Tyr
250                               255                               260

acc aca ggc cag gtg ttt gat ttg tct gag aag tta gag cag tgc gaa      924
Thr Thr Gly Gln Val Phe Asp Leu Ser Glu Lys Leu Glu Gln Ser Glu
265                               270                               275

gcc caa ctg gga cgt gcc agt ttc atg ttg gcc tta gaa aca cat gac      972
Ala Gln Leu Gly Arg Gly Ser Phe Met Leu Gly Leu Glu Thr His Asp
280                               285                               290

cgc aag tgc gaa gac aaa ctt gcc aaa gct act aga gac agc tgt aaa      1020
Arg Lys Ser Glu Asp Lys Leu Ala Lys Ala Thr Arg Asp Ser Cys Lys
295                               300                               305

acc acc ata gaa gcc atc cat gga ctg atg tct cag gtt att aag gat      1068
Thr Thr Ile Glu Ala Ile His Gly Leu Met Ser Gln Val Ile Lys Asp
310                               315                               320                               325

aaa ctg ttt aat cag att aac gtt gct tagtt accaccaagt acttctcaaa      1120
Lys Leu Phe Asn Gln Ile Asn Val Ala
330

gctgggtgtgt ggaaggaaaa gaagctcaag taacactttt aaccagitta ccaaaactca      1180
gattagaaga ctaagggtgt gtgtgggtgtc ctgagtattt gcaactgtaat aaaactatca      1240
cgtgaaaaaa aaaaaaaaaa aa      1262

```

<210> 2
 <211> 334
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Ala Ala Ser Gly Ser Gly Met Ala Gln Lys Thr Trp Glu Leu Ala
 1 5 10 15
 Asn Asn Met Gln Glu Ala Gln Ser Ile Asp Glu Ile Tyr Lys Tyr Asp
 20 25 30
 Lys Lys Gln Gln Gln Glu Ile Leu Ala Ala Lys Pro Trp Thr Lys Asp
 35 40 45
 His His Tyr Phe Lys Tyr Cys Lys Ile Ser Ala Leu Ala Leu Leu Lys
 50 55 60
 Met Val Met His Ala Arg Ser Gly Gly Asn Leu Glu Val Met Gly Leu
 65 70 75 80
 Met Leu Gly Lys Val Asp Gly Glu Thr Met Ile Ile Met Asp Ser Phe
 85 90 95
 Ala Leu Pro Val Glu Gly Thr Glu Thr Arg Val Asn Ala Gln Ala Ala
 100 105 110
 Ala Tyr Glu Tyr Met Ala Ala Tyr Ile Glu Asn Ala Lys Gln Val Gly
 115 120 125

sequence list.txt

Arg Leu Glu Asn Ala Ile Gly Trp Tyr His Ser His Pro Gly Tyr Gly
 130 135 140
 Cys Trp Leu Ser Gly Ile Asp Val Ser Thr Gln Met Leu Asn Gln Gln
 145 150 155 160
 Phe Gln Glu Pro Phe Val Ala Val Val Ile Asp Pro Thr Arg Thr Ile
 165 170 175
 Ser Ala Gly Lys Val Asn Leu Gly Ala Phe Arg Thr Tyr Pro Lys Gly
 180 185 190
 Tyr Lys Pro Pro Asp Glu Gly Pro Ser Glu Tyr Gln Thr Ile Pro Leu
 195 200 205
 Asn Lys Ile Glu Asp Phe Gly Val His Cys Lys Gln Tyr Tyr Ala Leu
 210 215 220
 Glu Val Ser Tyr Phe Lys Ser Ser Leu Asp Arg Lys Leu Leu Glu Leu
 225 230 235 240
 Leu Trp Asn Lys Tyr Trp Val Asn Thr Leu Ser Ser Ser Ser Leu Leu
 245 250 255
 Thr Asn Ala Asp Tyr Thr Thr Gly Gln Val Phe Asp Leu Ser Glu Lys
 260 265 270
 Leu Glu Gln Ser Glu Ala Gln Leu Gly Arg Gly Ser Phe Met Leu Gly
 275 280 285
 Leu Glu Thr His Asp Arg Lys Ser Glu Asp Lys Leu Ala Lys Ala Thr
 290 295 300
 Arg Asp Ser Cys Lys Thr Thr Ile Glu Ala Ile His Gly Leu Met Ser
 305 310 315 320
 Gln Val Ile Lys Asp Lys Leu Phe Asn Gln Ile Asn Val Ala
 325 330

<210> 3
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer for WNV-Cp amplification

<400> 3
 ccggaattct ctaaaaacc aggtggcccc gg

32

<210> 4
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer for WNV-Cp amplification

<400> 4
 gactagcggc cgcaccgcgc catcgagctc gcc

33

<210> 5
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer for DNA sequencing

sequence list.txt

<400> 5
ctattcgatg atgaagatac cccaccaaac cc

32

<210> 6
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for DNA sequencing

<400> 6
tagcatctat gacttttttg ggcgttcaag tga

33

<210> 7
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for WNV-Cp amplification

<400> 7
gactagcggc cgcacccgcg catccctagg cgc

33

PCTA9408-8

5/7

PCT REQUEST

Original (for SUBMISSION)

VIII-5-1	Declaration: Non-prejudicial disclosure or exceptions to lack of novelty Declaration as to non-prejudicial disclosures or exceptions to lack of novelty (Rules 4.17(v) and 51bis.1(a)(v)): Name (LAST, First)	in relation to this international application declares that the subject matter claimed in this international application was disclosed as follows:
VIII-5-1(i)	Kind of disclosure:	publication
VIII-5-1(i)	Date of disclosure:	16 April 2004 (16.04.2004)
VIII-5-1(i)	Title of disclosure:	Jab1, a nuclear exporter that mediates nucleus-cytosol translocation and degradation fo its substrates
VIII-5-1(i)	Place of disclosure:	
VIII-5-1(v)	This declaration is made for the purposes of:	all designations

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR2004/002190

A. CLASSIFICATION OF SUBJECT MATTER**IPC7 A61K 38/16**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 A61K 38/16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NCBI pubmed database, NCBI blastn database, Delphion Research Intellectual Property network database,,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Seeger M et al. 'A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits' In FASEB J. 1998 vol.12, No.6, p469-78. see entire document	1-19
A	Park KJ et al. 'Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2' In J.Biol.Chem.. 2003 vol.278, No.33, p30711-8. see entire document	1-19
A	Sharma S et al. 'Triggering the interferon antiviral response through an IKK-related pathway.' In Science.. 2003 vol.300, No.5622, p1148-51. see entire document	1-19
A	Soo HM et al. 'Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES' In Virology. 2002 vol.303, No.2, p253-77. see entire document	1-19
A	Tsutsumi T et al. 'Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein.' In Virology. 2002 vol.304, No.2, p415-24. see entire document	1-19

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

17 JUNE 2005 (17.06.2005)

Date of mailing of the international search report

17 JUNE 2005 (17.06.2005)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LIM, Hea Joon

Telephone No. 82-42-481-5600



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2004/002190

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material



a sequence listing



table(s) related to the sequence listing

b. format of material



in written format



in computer readable form

c. time of filing/furnishing



contained in the international application as filed



filed together with the international application in computer readable form



furnished subsequently to this Authority for the purposes of search

2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments: